Cutis 2022
DOI: 10.12788/cutis.0432
|View full text |Cite
|
Sign up to set email alerts
|

Views and Beliefs of Vitiligo Patients in Online Discussion Forums: A Qualitative Study

Abstract: Individuals with chronic illnesses turn to online communities to engage in asynchronous peer-to-peer exchanges to better understand and manage their disease. Messages and advice exchanged by online users with vitiligo are not well characterized. We conducted a qualitative study to explore the content exchanged by individuals with vitiligo in online forums. An interpretive research paradigm was utilized to assess public online forum content. A systematic search using the phrases online forum vitiligo support, v… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 27 publications
0
2
0
Order By: Relevance
“…Figure 1 shows the PRISMA flow diagram of the selection criteria. A total of 1398 studies were screened, and 249 studies (17.8%) were ultimately included in the database …”
Section: Resultsmentioning
confidence: 99%
“…Figure 1 shows the PRISMA flow diagram of the selection criteria. A total of 1398 studies were screened, and 249 studies (17.8%) were ultimately included in the database …”
Section: Resultsmentioning
confidence: 99%
“…The US Food and Drug Administration (FDA) PRO Guidance and draft Patient-Focused Drug Development (PFDD) Guidance provide standards for sponsors to achieve when selecting, developing or validating PRO measures for use in pharmaceutical clinical trials [6,7]. Considering the known and considerable psychological burden [8], distress [9], stigmatization [9], uncertainty around disease progression [10,11] and impairment of quality of life [8] associated with vitiligo, it is important to have valid, reliable and responsive PRO measures to evaluate patient-relevant experiences in clinical trials and allow patients to report directly on their wellbeing. Ultimately, PRO data can facilitate our understanding of the efficacy of investigational treatments and inform clinical decision making.…”
Section: Introductionmentioning
confidence: 99%